On December 4, 2025 PreciseDx, the leading innovator behind PreciseBreast, a novel AI digital pathology test, reported the upcoming presentation of three abstracts that further validate the test’s ability to assess risk of recurrence in early-stage breast cancer. Ongoing studies aim to demonstrate PreciseBreast’s ability to predict treatment benefit.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Three abstracts will be presented during the annual San Antonio Breast Cancer Symposium (SABCS) taking place December 9-12, 2025, in San Antonio, TX. These presentations underscore the growing momentum and clinical success of PreciseBreast which utilizes our proprietary AI platform to combine AI-enabled image feature data with key clinical factors to deliver a PreciseBreastⓇ Score that accurately stratifies patients by recurrence risk.
SABCS-accepted abstracts presented by PreciseDx
PS113-13: Clinical validation of an Artificial Intelligence digital pathology-based prognostic test to predict risk of recurrence using biopsy specimens from patients with invasive breast cancer
Author/Presented by: Michael J. Donovan, PhD, MD
Poster Presentation: Wednesday, December 10, 2025, 12:30 PM – 2:00 PM
PS4-12-28: A novel approach for phenotyping triple negative breast cancer using an Artificial Intelligence digital pathology-based prognostic test to assess recurrence risk and response to therapy
Author/Presented by: Nicholas Stanzione MD, David Geffen School of Medicine, UCLA
Poster Presentation: Thursday, December 11, 2025, 5:00 PM – 6:30 PM
SABCS-accepted abstract presented by Lankenau Medical Center/Main Line Health
PS3-06-02: Prospective Evaluation of "PreciseBreast" AI Tool in Early-Stage Invasive Breast Cancer Risk Stratification
Author/Presented by: Lankenau Medical Center, Main Line Health, Talar Telvizian, MD
Poster Presentation: Thursday, December 11, 2025, 12:30 PM – 2:00 PM
"These results build on our prior publications validating PreciseBreast’s clinical and analytical accuracy in early-stage invasive breast cancer by demonstrating the ability to use the patient’s biopsy specimen to risk stratify as well as advancing our understanding of patients with triple negative breast cancer," shared Eric Converse, CEO of PreciseDx. "We’re particularly excited about the independent, real-world experience at Lankenau Medical Center using PreciseBreast in patients with HR+, HER2- early breast cancer and continuing our collaboration with NSABP to further evaluate PreciseBreast’s ability to predict chemotherapy benefit in this population."
(Press release, PreciseDx, DEC 4, 2025, View Source [SID1234661144])